Your Messages Inbox
Your Article Summary
See Latest ArticlesXenoPort Announces Initiation of a Phase 2b Clinical Trial of Arbaclofen Placarbil in Patients with Gastroesophageal Reflux Disease
XenoPort, 10/20/09
XenoPort, Inc. announced that it has initiated a Phase 2b clinical trial of arbaclofen placarbil, also known as XP19986, in patients with gastroesophageal reflux disease who remain symptomatic despite treatment with a proton pump inhibitor. The trial is a multi–center, randomized, double–blind, placebo–controlled study designed to assess the efficacy and safety of AP as adjunctive therapy to PPIs.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease
New England Journal of Medicine, 11/20/09
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09
Article Search
Sponsor